Tagged with

Brazil A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera after a failed merger attempt, and Quantoom, Univercells and Fiocruz’s RNA-based vaccine production collaboration.   MediPharm Labs Enters Landmark Commercial…

Puerto Rico Antonio Medina, CEO of Convergent Strategies, shares insights into Puerto Rico’s evolving economic landscape and the critical role his consultancy plays in driving growth and innovation across industries. He reflects on his experience guiding the island out of bankruptcy as a member of the Financial Oversight Board and discusses key…

Saudi Arabia Marwan Omar, General Manager of Ferring in the GCC, lays out the company’s growth strategy and its deep commitment to the region. With a focus on local talent development, strategic partnerships, and expanding its product portfolio, Ferring continues to strengthen its presence in reproductive medicine, gastroenterology, and uro-oncology.   Investing…

Saudi Arabia Mohamed Al Holibi, Regional Business Lead for Health Information Systems at Solventum, shares insights into the evolving role of healthcare data and digital transformation in Saudi Arabia. In this interview, he discusses Solventum’s commitment to supporting Vision 2030 through advanced AI-driven technologies, the implementation of Diagnosis-Related Groups (DRG) systems, and…

Global Regular PharmaBoardroom contributor David H. Crean outlines the resilient and cautious optimism observed at JPM 2025, the annual healthcare financing conference held near San Francisco’s Union Square. While uncertainties and headwinds still persist, particularly around regulatory changes, affordability issues, and capital financing in the public and private markets, the healthcare…

Mexico This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth. By balancing structure with inclusivity, Ortiz implements best practices drawn from global experience while respecting GLR’s legacy as a family-owned…

Global Drawing on insights from DIA’s 2024 Global Annual Meeting, Martin Hodosi and Rosanna Lim of Kearney Healthcare and Life Sciences examine some of the key ethical challenges around integrating AI into healthcare.   Artificial intelligence (AI) has already begun transforming the healthcare industry, with applications ranging from diagnostics to drug…

Europe James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe.   In an era where artificial intelligence (AI) is revolutionizing healthcare and clinical research, regulatory bodies are racing to keep pace. The…

Global In 2024, global biopharma faced a challenging landscape shaped by geopolitical tensions and cost containment measures in key markets. Despite these pressures, most major players perhaps surprisingly opted to retain their CEOs, focusing instead on reshaping management at other levels. Companies like Bayer underwent sweeping transformations, while others, such as…

France François Bayrou’s new administration in France, sworn in after the previous, three-month-old government was toppled by a no-confidence vote, brings a new health minister to a post recently characterized by instability. With budget concerns looming and the doubtful staying power of the new cabinet, it remains to be seen how…

China A summary of some of the latest news from China’s pharma industry, including AbbVie’s blood cancer licensing option with Simcere; Lonza’s China manufacturing expansion; Merck’s obesity deal with Hansoh Pharma; Candid Therapeutics’ T-cell engager agreement with WuXi Biologics, and the DLL3-targeted antibody parternship between Innovent Biologics and Roche. AbbVie secures…

Mexico Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical role in Lilly’s global strategy. Alcazar offers insights into the company’s focus on innovation, diversity, and patient-centricity, as well as…